Recent News

• 11.05.2026 - electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
• 11.04.2026 - electroCore Announces Third Quarter 2026 Financial Results
• 10.29.2026 - electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
• 10.28.2026 - electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
• 10.27.2026 - fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
• 10.21.2026 - electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
• 09.10.2026 - electroCore to Participate at H.C. Wainwright Global Investment Conference
• 09.09.2026 - electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
• 08.25.2026 - electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
• 08.06.2026 - electroCore Announces Second Quarter 2026 Financial Results

Recent Filings

• 11.04.2026 - EX-99.1 EX-99.1
• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 09.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.18.2026 - 4/A Statement of changes in beneficial ownership of securities
• 09.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities